Abstract:It has been reported that CDK8 plays a key role in acute myeloid leukaemia. Here, a total of 40 compounds were rational designed and synthesised based on the previous SAR. Among them, compound 12 ( 3-(3-(furan-3-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzamide ) showed the most potent inhibiting activity against CDK8 with an IC 50 value of 39.2 ± 6.3 nM and anti AML cell proliferation activity (molm-13 GC 50 = 0.02 ± 0.01 μ M, MV4-11 GC 50 = 0.03 ± 0.01 μ M). Mechanistic studies revealed that this compound 12 could inhibit the phosphorylation of STAT-1 and STAT-5. Importantly, compound 12 showed relative good bioavailability ( F = 38.80%) and low toxicity in vivo . This study has great significance for the discovery of more efficient CDK8 inhibitors and the development of drugs for treating AML in the future.

What problem does this paper attempt to address?

This paper attempts to solve the key problems in the treatment of acute myeloid leukemia (AML). Specifically, the paper focuses on the development of new and highly effective CDK8 inhibitors to treat AML by inhibiting the phosphorylation of STAT1 and STAT5. ### Background and Problems 1. **The Current Situation of AML Treatment** - AML is a highly heterogeneous disease, originating from the malignant clonal proliferation of abnormally differentiated bone marrow cells, and is difficult to treat. - In the past 40 years, the standard initial chemotherapy regimens (such as daunorubicin or idarubicin and cytarabine) can only achieve a complete remission rate of 70 - 80%, and there is an inherent disease resistance. - With the emergence of more targeted inhibitors, such as IDH1/IDH2 inhibitors, FLT3 inhibitors and BCL - 2 inhibitors, the treatment effect of AML has been improved, but new targeted inhibitors still need to be discovered, especially for drug - resistant patients. 2. **The Role of CDK8 in AML** - CDK8 plays a key role in AML and can positively regulate the phosphorylation of STAT1 and STAT5. - It has been reported that CDK8 inhibitors such as SEL120 - 34A can inhibit the phosphorylation of STAT1 S727 and STAT5 S726 in AML cells and have entered the clinical trial stage. - However, due to toxicity and pharmacokinetic problems, no existing CDK8 inhibitors have been commercialized. ### Research Objectives - **Design and Synthesis of New CDK8 Inhibitors**: Based on the rational design of structure - activity relationship (SAR), synthesize 40 compounds and screen out candidate molecules that highly inhibit CDK8. - **Evaluation of the Biological Activity of Compounds**: Test the inhibitory activity of compounds on CDK8 and the inhibitory effect on AML cell proliferation. - **Mechanism Research**: Explore the influence of compounds on the phosphorylation of STAT1 and STAT5 and verify their mechanism of action. - **Pharmacokinetic and Safety Evaluation**: Evaluate the in - vivo pharmacokinetic properties and safety of compounds to provide data support for future drug development. ### Main Findings - **High - Efficiency Inhibitory Activity of Compound 12**: Compound 12 (3-(3-(furan - 3 - yl)-1H - pyrrolo[2,3 - b]pyridin - 5 - yl)benzamide) exhibits the strongest CDK8 inhibitory activity, with an IC50 value of 39.2 ± 6.3 nM, and has a significant inhibitory effect on AML cell proliferation (molm - 13 GC50 = 0.02 ± 0.01 μM, MV4 - 11 GC50 = 0.03 ± 0.01 μM). - **Mechanism Research**: Compound 12 can inhibit the phosphorylation of STAT1 S727 and STAT5 S726. - **Pharmacokinetics and Safety**: Compound 12 has good bioavailability (F = 38.80%), low toxicity, and shows good pharmacokinetic characteristics in vivo. ### Conclusions - This study provides important guidance for the discovery of more efficient and safe CDK8 inhibitors and is expected to be used for the treatment of AML in the future. Through these studies, the authors hope to provide new targeted drugs for the treatment of AML, especially for those patients who are resistant to existing drugs.

Discovery of novel and potent CDK8 inhibitors for the treatment of acute myeloid leukaemia

Design and Synthesis of 7-Azaindole Derivatives As Potent CDK8 Inhibitors for the Treatment of Acute Myeloid Leukemia

Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia

Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.

Discovery of novel and bioavailable histone deacetylases and cyclin-dependent kinases dual inhibitor to impair the stemness of leukemia cells

Discovery of Potent and Selective PI3Kδ Inhibitors for the Treatment of Acute Myeloid Leukemia

Discovery of Dual CDK6/PIM1 Inhibitors with a Novel Structure, High Potency, and Favorable Druggability for the Treatment of Acute Myeloid Leukemia

Discovery of Novel Glycogen Synthase Kinase-3Α Inhibitors: Structure-based Virtual Screening, Preliminary SAR and Biological Evaluation for Treatment of Acute Myeloid Leukemia.

Discovery of Novel 2-Aminopyridine-Based and 2-Aminopyrimidine-Based Derivatives as Potent CDK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors and Hematological Malignancies

Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity

Rational discovery of dual FLT3/HDAC inhibitors as a potential AML therapy

Discovery of novel selective phosphodiesterase‐1 inhibitors for the treatment of acute myelogenous leukemia

Design, Synthesis, and Evaluation of Pyrido.[3,4-B]pyrazin-2(1h)-one Derivatives As Potent FLT3 Inhibitors

Discovery of ( R )-4-(8-methoxy-2-methyl-1-(1-phenylethy)-1 H -imidazo[4,5- c ]quinnolin-7-yl)-3,5-dimethylisoxazole as a potent and selective BET inhibitor for treatment of acute myeloid leukemia (AML) guided by FEP calculation

Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities.

Identification of Potent CDK9 Inhibitors with Novel Skeletons Via Virtual Screening, Biological Evaluation, and Molecular Dynamics Simulation

A Novel Methoxybenzyl 5-Nitroacridone Derivative Effectively Triggers G1 Cell Cycle Arrest in Chronic Myelogenous Leukemia K562 Cells by Inhibiting CDK4/6-Mediated Phosphorylation of Rb

Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2h-pyran-4-carbonitrile (JSH-150) As a Novel Highly Selective and Potent CDK9 Kinase Inhibitor.

Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer

Discovery and Characterization of a Novel Potent Type II Native and Mutant BCR-ABL Inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)

Design, synthesis, and pharmacological evaluation of novel benzothiazole derivatives targeting LCK in acute lymphoblastic leukemia